A detailed history of Kaizen Financial Strategies transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Kaizen Financial Strategies holds 2,407 shares of GILD stock, worth $264,649. This represents 0.13% of its overall portfolio holdings.

Number of Shares
2,407
Holding current value
$264,649
% of portfolio
0.13%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$83.95 - $97.9 $202,067 - $235,645
2,407 New
2,407 $222,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $138B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Kaizen Financial Strategies Portfolio

Follow Kaizen Financial Strategies and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kaizen Financial Strategies, based on Form 13F filings with the SEC.

News

Stay updated on Kaizen Financial Strategies with notifications on news.